



Merck KGaA, Darmstadt, Germany – Berenberg European Conference 2013

Dr. Stefan Oschmann

Member of the Executive Board, Biopharmaceuticals & Consumer Health

Merck KGaA
Darmstadt · Germany

London, 4 December 2013



Disclaimer

Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate under the umbrella brand EMD.

To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and business descriptions of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada.

Disclaimer

Remarks

All comparative figures relate to the corresponding last year's period.

Important information

This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities in the United States. The shares referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration under the Securities Act or an available exemption from such registration.

Note regarding forward-looking statements

The information in this document may contain "forward-looking statements". Forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "will" or words of similar meaning and include, but are not limited to, statements about the expected future business of Merck KGaA, Darmstadt, Germany. These statements are based on the current expectations of management of Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt, Germany, and are inherently subject to uncertainties and changes in circumstances. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are changes in global, political, economic, business, competitive, market and regulatory forces. Merck KGaA, Darmstadt, Germany and E. Merck KG, Darmstadt, Germany do not undertake any obligation to update the content of this presentation and forward-looking statements to reflect actual results, or any change in events, conditions, assumptions or other factors. All trademarks mentioned in the presentation are legally protected.

Agenda





Company overview

Transforming the company


Business overview on Biopharmaceuticals

Financials and guidance

A balanced portfolio of four divisions


Merck KGaA, Darmstadt, Germany			
<h3>Biopharmaceuticals</h3>  <p>Leading in certain specialty pharma markets</p> <ul style="list-style-type: none">▪ Life cycle management▪ Biologics▪ Emerging markets	<h3>Consumer Health</h3>  <p>Present in OTC niche markets</p> <ul style="list-style-type: none">▪ Vitamins▪ Supplements▪ Strong presence in Latin America and Europe	<h3>Performance Materials</h3>  <p>No. 1 in display materials</p> <ul style="list-style-type: none">▪ Customer intimacy▪ Innovation power▪ Cost and technology leadership	<h3>Life Science</h3>  <p>Top 3 in life science tools</p> <ul style="list-style-type: none">▪ Global presence▪ Innovation▪ End-to-end solutions for pharma industry

Strong businesses with attractive margins




*EBITDA pre margin in % of sales
**Including Corporate/Others (-€48.9 m)

Emerging Markets and Japan drive organic growth, reported sales burdened by strong FX headwinds




*Australia/Oceania, Africa

We have added scale while strengthening the attractiveness of assets in our portfolio



*Except "Crop Bioscience", which was divested
**Except "Theramex", which was divested

Our stronger portfolio has enabled us to fundamentally improve our profitability



*adjusted EBIT** divided by total revenues

**adjusted EBIT is EBIT less costs related to acquisitions (amortization and impairments of intangible assets, and integration costs) and less exceptionals

Agenda

















Company overview




Transforming the company

Business overview on Biopharmaceuticals


Financials and guidance

Portfolio evolution improved our profitability structure, but further potential remains


Assessment of long-term financial performance relative to peers				
	Sales growth	Gross margin	SG&A	R&D productivity
Biopharmaceuticals				
Consumer Health				
Performance Materials				
Life Science				

 above peers
  in-line with peers
  below peers

We now focus on growth




New management in key positions and across the entire organization




Fit for 2018: Strict implementation to yield ~€385 m savings until 2018

Net annual savings							
Savings	2012	2013	2014	2015	2016	2017	Total
Biopharmaceuticals	100	250	300				300
Consumer Health	10	15	25				25
Perform. Materials	5	10	20				20
Life Science		5	10	20	30	40	40
Total	115	280	355	365	375	385	385
Costs*	463	229	110	15			817



* Fit for 2018 one-time costs on EBIT (also including related one-time D&A = Fit for 2018 impairments)

9M 2013 – Transformation well on track



Agenda

Company overview


Transforming the company

Business overview on Biopharmaceuticals


Financials and guidance

Biopharmaceuticals – Key strengths


Addressing therapeutic areas with high unmet medical needs	
Business characteristics	<ul style="list-style-type: none">▪ Specialty pharma growth of ~5%▪ Global leader in Multiple Sclerosis, Oncology and Fertility▪ Less risk from “patent cliff”
Clear competencies	<ul style="list-style-type: none">▪ Development and manufacturing of biologics▪ Strong life cycle management▪ Focus on oncology
Market position	<ul style="list-style-type: none">▪ Leading in key therapeutic areas▪ Leading brands addressing unmet medical needs▪ Emerging Markets strength with trend to increasing access to healthcare



Rebif continues to be an important asset




Erbitux – outstanding performance in Emerging Markets and Japan drive organic growth



*Australia/Oceania, Africa

Biopharmaceuticals – a balanced portfolio with Fertility, Endocrinology and GM driving organic growth



*Organic sales growth Q3 2013

Agenda for value creation and for continuous improvement of business platform

Improve R&D effectiveness

- ▶ Portfolio review
- ▶ Increased externalization of development
- ▶ Strengthen early-stage pipeline / In-licensing
- ▶ Enhance biomarker / stratified medicine

Focus on operational excellence





- ▶ Review cost structure
- ▶ Reduce organizational complexity

Top-line growth


- ▶ Focus on Rebif defense
- ▶ Sustain Erbitux growth
- ▶ Aggressively drive business in Emerging Markets



Examples of access to external capabilities


Research		<ul style="list-style-type: none"> ▪ Platform to discover a novel class of antibody derived therapeutic proteins ▪ Collaborations in the therapeutic areas of immunology, oncology and osteoarthritis ▪ Currently 2 projects in pre-clinical testing
		<ul style="list-style-type: none"> ▪ Collaboration focusing on lead discovery and lead optimization in cancer metabolism ▪ Jointly discover small molecule based drugs to deliver potential first-in-class molecules
Development		<ul style="list-style-type: none"> ▪ Unique strategic collaboration for development and clinical trial execution ▪ Commitment to cost-disciplined science ▪ Optimizing productivity and execution of studies with focus on quality and efficiency
		<ul style="list-style-type: none"> ▪ In-licensing of SYM 004, a mixture of two EGFR-antibodies ▪ Currently in Phase I/II ▪ Potential to build on existing Erbitux franchise

Increased in-licensing has enriched the pipeline



Acronyms: mCRC: Malignant Colorectal Cancer; MS: Multiple Sclerosis; SSCHN: Squamous Cell Carcinoma of the Head and Neck; MM: Malignant melanoma; PC: Pancreatic Cancer; LGOC: Low Grade Ovarian Cancer; mCRPC: Metastatic Castration-Resistant Prostate Cancer; SLE: Systemic Lupus erythematosus; OA: Osteoarthritis; STS: Soft Tissue Sarcoma; NSCLC: Non-Small-Cell Lung Cancer; PKU: Phenylketonuria; Pipeline as of November, 2013

Biopharmaceuticals pipeline more more balanced




- Dominated by phase III projects, using up large parts of the resources
- Early-stage pipeline too light

- Reduced number of phase III projects in core therapeutic areas (e.g. oncology)
- Shared risk with partners, also in late-stage development (e.g. TH-302)
- Early-stage pipeline strengthened (e.g. Sym004)

*START trial did not meet primary endpoint. INSPIRE study ongoing. Formerly also known as Stimuvax

Alliance with Dr. Reddy's: entering growing biosimilars markets



Agenda

Company overview

Transforming the company

Business overview on Biopharmaceuticals

Financials and guidance


9M 2013: Jump in profitability fueled by restructuring

[€ m]	9M 2013	9M 2012	Δ	
Sales	8,064	8,029	0%	9M 2013 <ul style="list-style-type: none"> ▪ Good organic sales growth of 4% is being offset by FX leading to stable top line development ▪ 340 bps EBITDA pre margin uplift reflects strong restructuring execution ▪ 2012 operating cash flow driven by exceptional working capital improvement ▪ Continuous net financial debt reduction reflecting strong cash-generating nature of business
EBITDA pre	2,458	2,175	13%	
<i>Margin (% of sales)</i>	<i>30.5%</i>	<i>27.1%</i>		
EPS pre [€]	6,66	5.56	20%	
Operating cash flow	1,785	2,074	-14%	
[€ m]	Sept 30, 2013	Dec 31, 2012	Δ	
Net financial debt	536	1,926	-72%	
Working capital	2,290	2,360	-3%	
Employees	37,976	38,847	-2%	
EBITDA and margin upgraded to a new level				





Upgrade of EBITDA pre group guidance

Group guidance for 2013	
Sales:	~ €10.7 - 10.9 bn
EBITDA pre:	~ €3.2 - 3.25 bn
EPS pre:	~ €8.50 - 9.00

On track to deliver



Precision of divisional 2013 guidance – Performance Materials and Consumer Health to come out stronger

Biopharmaceuticals	Consumer Health	Performance Materials	Life Science
			
Sales	Sales	Sales	Sales
Moderate organic growth	Moderate organic growth	Stable	Moderate organic growth
EBITDA pre	EBITDA pre	EBITDA pre	EBITDA pre
~ €1.9 – 2.0 bn	~ €73 - 77 m	~ €750 - 770 m	~ €620 – 640 m
Group 2013 guidance: ~ €3.2 – 3.25 billion EBITDA pre			




Merck KGaA

Darmstadt · Germany

Appendix

Additional financial guidance

Further financial details	
Royalty, license and commission income in 2014	To decline to: ~€180-200 m
Corporate EBITDA pre	~€-210 m
Underlying tax ratio	~25% to 26%
Capex on PPE	~€450 m
Hedging / USD assumption	2013 & 2014 hedge ratio around 40% at EUR/USD ~1.30 to 1.35



EBITDA pre improves while currency headwinds hurt

Q3 yoy sales	Organic	Currency	Portfolio	Total
Biopharmaceuticals	5%	-7%	0%	-2%
Consumer Health	15%	-8%	0%	7%
Performance Materials	-2%	-7%	0%	-9%
Life Science	6%	-7%	1%	-1%
The Group	5%	-7%	0%	-2%

Q3 yoy EBITDA pre contributors [€ m]



- Biopharmaceuticals and Life Science strongest absolute contributors to organic growth
- All divisions continue to experience significant currency headwinds, stemming mainly from the U.S. dollar and the Japanese yen
- Cost efficiencies and resource allocation in marketing and selling fuel Biopharmaceuticals improvement
- Corporate & Other reflects hedging gains and cost efficiencies

Q3 2013: Strong margin and profitability expansion amid significant FX headwinds

[€ m]	Q3 2013	Q3 2012	Δ	Q3 2013 dynamics
Sales	2,659	2,722	-2%	<ul style="list-style-type: none"> ▪ Sales decline slightly as solid organic growth of 5% is being more than offset by FX ▪ EBITDA pre increase driven by cost control and gains from proactive hedging approach ▪ Strong operating cash flow despite restructuring cash-outs of ~€45 m; previous year driven by exceptional improvements in working capital management ▪ Cash generating nature of portfolio drives net debt reduction
EBITDA pre	831	754	10%	
<i>Margin (% of sales)</i>	<i>31.2%</i>	<i>27.7%</i>		
EPS pre [€]	2.29	1.98	16%	
Operating cash flow	827	908	-9%	
[€ m]	Sept 30, 2013	Dec 31, 2012	Δ	
Net financial debt	536	1,926	-72%	
Working capital	2,290	2,360	-3%	
Employees	37,976	38,847	-2%	
Over ~€1.4 bn net financial debt reduction in nine months				


Reported earnings strong, driven by operational and financial improvements

[€ m]	Q3 2013	Q3 2012	Δ	Reported results
EBIT	482	318	51%	<ul style="list-style-type: none"> ▪ EBIT increases due to good business performance and lower one-time costs ▪ Strong debt deleveraging drives financial result improvement ▪ Lower tax rate, due to one-time tax benefits ▪ Increase of reported EPS reflects operational and financial improvements
Financial result	-52	-58	11%	
Profit before tax	430	260	65%	
Income tax	-87	-71	-23%	
<i>Tax ratio (%)</i>	<i>20%</i>	<i>27%</i>		
Net income	340	185	83%	
EPS (€)	1.56	0.85	83%	

Biopharmaceuticals: Good organic growth combined with strong margin improvement

[€ m]	Q3 2013	Q3 2012
Sales	1,483	1,511
Marketing and selling	-301	-339
Admin	-51	-59
R&D	-297	-287
EBIT	274	152
EBITDA	480	383
EBITDA pre	501	466
<i>Margin (% of sales)</i>	33.8%	30.8%


Sales bridge



Comments

- Solid organic sales growth of 5% driven by Emerging Markets and Japan; FX overshadows underlying growth
- Rebif - U.S. volume decline as guided
- Strong Erbitux performance driven by Emerging Markets & Japan
- Branded mature products outperforming in Emerging Markets
- Cost savings accelerated especially in marketing and selling
- Slight R&D increase due to investments in life-cycle management and increase in early stage projects
- Solid profitability improvement despite significant FX headwinds and loss of Avonex royalty income of ~€30 m in Q3


Q3 2013 share of group sales



Consumer Health: Turnaround fully on track

[€ m]	Q3 2013	Q3 2012	Comments
Sales	131	122	<ul style="list-style-type: none"> ▪ High organic sales growth driven by Germany, France & Emerging Markets as well as a soft comparable base, mitigated by FX ▪ Strategic brands (Kytta, Bion 3, Nasivin) show strong growth due to improved resource allocation and tightly managed expenses ▪ Restructuring efforts of product pruning and market exits continue to improve the business model ▪ Profitability improvement driven by sales growth while costs are kept under control
Marketing and selling	-55	-53	
Admin	-4	-5	
R&D	-4	-5	
EBIT	21	8	
EBITDA	23	11	
EBITDA pre	24	19	
<i>Margin (% of sales)</i>	<i>18.4%</i>	<i>15.7%</i>	


Sales bridge				
€122 m	15%	-8%	0%	€131 m
Q3 2012	Organic	Currency	Portfolio	Q3 2013

Q3 2013 share of group sales	
	Consumer Health 5%

Performance Materials: Liquid crystal mix and leaner Pigments & Cosmetics drive margin expansion

[€ m]	Q3 2013	Q3 2012
Sales	406	446
Marketing and selling	-35	-38
Admin	-7	-9
R&D	-37	-35
EBIT	177	164
EBITDA	202	194
EBITDA pre	197	197
<i>Margin (% of sales)</i>	<i>48.4%</i>	<i>44.2%</i>


Sales bridge



Comments

- Sales down due to strong FX and moderate inventory destocking
- Healthy demand for continuously improved flagship technologies PS-VA and IPS support volumes and profitability
- Market shares kept at high levels due to product innovation and trend to larger displays
- Faster implementation of Pigments efficiency measures, leading to visible improvement of profitability versus previous years
- EBITDA pre stable due to favorable mix in liquid crystals and improved Pigments cost structure offsetting FX headwinds
- Inventory destocking expected to become more visible in Q4


Q3 2013 share of group sales



Life Science: Resilient portfolio delivers solid sales and profitability despite difficult environment

[€ m]	Q3 2013	Q3 2012
Sales	639	643
Marketing and selling	-171	-166
Admin	-25	-26
R&D	-40	-43
EBIT	67	68
EBITDA	145	145
EBITDA pre	157	152
<i>Margin (% of sales)</i>	<i>24.6%</i>	<i>23.7%</i>


Sales bridge



Comments

- Volume and price increases in Process and Lab Solutions compensate for U.S. sequestration pressure in Bioscience (-8%*)
- Solid organic performance and portfolio effects are offset by FX headwinds (Japanese yen and U.S. dollar)
- All business units with double-digit organic growth in Emerging Markets and ongoing solid performance in Europe
- Continued biopharma demand drives volume and price increases in Process Solutions
- Despite difficult economic environment business proves resilient maintaining high profit and cash contribution

Q3 2013 share of group sales



*reported

Balance sheet: Deleveraging continues

[€ m]	Sept 30, 2013	Dec 31, 2012		Sept 30, 2013	Dec 31, 2012
Current assets	7,374	6,626	Net equity	10,781	10,415
Cash and cash equivalents	915	730	Current liabilities	4,080	4,562
Marketable securities and financial assets	2,392	1,798	Current financial liabilities	568	1,091
Trade accounts receivable	2,053	2,115	Trade accounts payable	1,329	1,288
Inventories	1,566	1,534	Other current liabilities	1,072	1,096
Other current assets	361	272	Income tax liabilities	535	401
Income tax receivables	87	179	Current provisions	576	684
Non-current assets	13,953	15,017	Non-current liabilities	6,465	6,667
Intangible assets	10,281	10,945	Non-current financial liabilities	3,274	3,362
Property, plant and equipment	2,592	2,954	Other non-current liabilities	6	9
Non-current financial assets	75	97	Non-current provisions	1,002	892
Other non-current assets	95	75	Prov. for pensions / other	1,240	1,212
Deferred tax assets	909	947	Deferred tax liabilities	943	1,192
Total assets	21,326	21,643	Total liabilities and equity	21,326	21,643

- Cash position increases, despite redemption of €750 m eurobond in September
- Ongoing deleveraging leading to comfortable gearing ratios

Another quarter of strong cash generation


[€ m]	Q3 2013	Q3 2012	Δ	Cash flow drivers
Profit after tax	343	189	154	<ul style="list-style-type: none"> ▪ High profit after tax due to strong underlying business performance and lower restructuring charges ▪ Lower amortization from Avonex and Enbrel reduced D&A ▪ Operational cash flow down as prior year benefitted from new working capital management ▪ Financing activities reflect €750m bond repayment in September 2013 ▪ Q4 expected sequentially at more moderate level due to seasonal cash items
D&A	315	343	-28	
Changes in provisions	32	121	-88	
Changes in other assets / liabilities	76	54	21	
Other operating activities	-8	-2	-6	
Operating cash flow before changes in WC	758	705	53	
Changes in working capital	69	203	-134	
Operating cash flow	827	908	-81	
Investing cash flow	-20	-397	377	
thereof Capex*	-78	-64	-14	
Financing cash flow	-745	-76	-669	

*Only PPE without intangibles

Biopharmaceuticals and Performance Materials key contributors to EBITDA pre increase

9M yoy sales	Organic	Currency	Portfolio	Total
Biopharmaceuticals	4%	-4%	0%	0%
Consumer Health	8%	-4%	0%	3%
Performance Materials	4%	-4%	0%	0%
Life Science	5%	-4%	1%	2%
The Group	4%	-4%	0%	0%

9M yoy EBITDA pre contributors [€ m]




- Solid organic growth within all divisions with Biopharmaceuticals and Life Science as highest absolute contributors
- Group sales flat as strong currency headwinds offset organic growth
- EBITDA pre increase mainly driven by better cost structure, positive product mix and organic growth in all divisions
- Corporate & Other supported bottom line result with yoy hedging delta of ~€65 m

Biopharmaceuticals: Good organic growth and swift cost savings implementation boost margin

[€ m]	9M 2013	9M 2012
Sales	4,468	4,474
Marketing and selling	-965	-1,030
Admin	-154	-166
R&D	-918	-916
EBIT	752	328
EBITDA	1,407	1,034
EBITDA pre	1,455	1,318
<i>Margin (% of sales)</i>	32.6%	29.5%


Sales bridge




Comments

- Sales virtually stable as ongoing good organic momentum in Emerging Markets is being offset by adverse currency effects
- Rebif price increases in U.S. trigger organic growth - being mitigated by softening volumes
- Erbitux performs at 5% organic growth driven by Emerging Markets and strong support from head and neck launch in Japan
- Visible cost containment in marketing & selling and administration
- R&D contains investments in life-cycle management as well as early oncology projects
- Profitability increases on savings and yield variances


9M 2013 share of group sales



Biopharmaceuticals organic growth by product




General Medicine continues to expand in Emerging Markets while Fertility and Endocrinology remain flat



*formerly "Cardiometabolic Care & General Medicine and Others"

Biopharmaceuticals pipeline




Pipeline as of Sept, 2013; ¹Combined with PI3K/mTOR inhibitor of Sanofi (SAR245409), conducted under the responsibility of Merck KGaA, Darmstadt, Germany
²Sponsored by the National Cancer Institute (NCI), USA; ³Phase IIIb post-approval request by EMA; ⁴FORWARD study on-going; ⁵ADDRESS II study in preparation
⁶START2 study in preparation. INSPIRE study ongoing

Consumer Health: Healthy organic growth and execution of efficiency measures drive profitability

[€ m]	9M 2013	9M 2012
Sales	363	351
Marketing and selling	-159	-159
Admin	-13	-15
R&D	-12	-14
EBIT	51	24
EBITDA	58	33
EBITDA pre	58	47
<i>Margin (% of sales)</i>	<i>15.9%</i>	<i>13.5%</i>


Sales bridge



Comments

- Higher sales on strong organic increase mitigated by adverse currency effects
- Solid organic growth in Emerging Markets and Europe, as key elements of top-line increase
- Strong performance of cough and cold and vitamin products, especially Bion 3 and Nasivin, mainly stemming from Europe
- Foster growth of core products through focused resource allocation
- Improved profitability driven by focus on strategic products, cost containment and exit from unprofitable markets lacking scale


9M 2013 share of group sales



Performance Materials: Pigments restructuring and liquid crystals leadership increase profitability

[€ m]	9M 2013	9M 2012
Sales	1,259	1,259
Marketing and selling	-107	-106
Admin	-22	-24
R&D	-107	-102
EBIT	519	477
EBITDA	611	565
EBITDA pre	613	553
<i>Margin (% of sales)</i>	<i>48.7%</i>	<i>44.0%</i>


Sales bridge



Comments

- Sales stable as organic growth and currency headwinds offset each other
- Focus on improving existing and developing future technologies to maintain high market shares are elements of R&D increase
- Global display trends drive demand for large TVs and tablets resulting in shift towards PS-VA and IPS technologies
- Pigments supporting business with strong Xirallic volumes in Europe as well as implementation of efficiency measures
- Changes in product mix, good capacity utilization and cost control drive margin improvement


9M 2013 share of group sales



Life Science: Proven resilience amid U.S. sequestration and FX headwinds

[€ m]	9M 2013	9M 2012
Sales	1,974	1,945
Marketing and selling	-514	-502
Admin	-75	-78
R&D	-121	-122
EBIT	211	221
EBITDA	444	449
EBITDA pre	475	471
<i>Margin (% of sales)</i>	<i>24.1%</i>	<i>24.2%</i>


Sales bridge



Comments

- Price and volume increases are mitigated by FX mainly due to the devaluation of the Japanese yen
- Ongoing healthy demand from biopharmaceutical industry especially for single use products drive Process Solutions growth
- Mid-single digit Lab Solutions growth led by Biomonitoring and strong Lab Water performance in the U.S.
- Bioscience performance impacted by U.S. healthcare budget constraints, overshadowing good performance in Europe
- Slight increase in EBITDA pre on higher volumes and prices despite higher costs in marketing & selling as field force enlarges


9M 2013 share of group sales




Solid operating cash flow in 9M 2013

[€ m]	9M 2013	9M 2012	Δ	Cash flow drivers
Profit after tax	928	303	624	<ul style="list-style-type: none"> ▪ Higher profit after tax due to good operational business performance; prior year included restructuring ▪ Changes in provisions for 9M 2012 including provisions for restructuring measures ▪ Other assets and liabilities decrease due to lower tax payments ▪ Improvement in working capital management drives 2012 operating cash flow ▪ Investing cash flow up due to higher investment in marketable securities, despite cash-in from Geneva HQ sale ▪ Financing cash flow contains bond repayments in 2012 and 2013
D&A	997	1,037	-41	
Changes in provisions	35	551	-516	
Changes in other assets / liabilities	-56	-217	161	
Other operating activities	-47	-26	-21	
Operating cash flow before changes in WC	1,857	1,649	208	
Changes in working capital	-72	425	-497	
Operating cash flow	1,785	2,074	-289	
Investing cash flow	-612	-584	-27	
thereof Capex*	-235	-181	-54	
Financing cash flow	-966	-944	-23	


External growth criteria

Strategic criteria	<ul style="list-style-type: none">▶ Portfolio fit: Innovations for specialty markets▶ Complementary to business model: Customer intimacy and leading positions▶ Cultural fit	
Financial criteria	<ul style="list-style-type: none">▶ EPS accretive in one to three years for commercial asset acquisitions▶ Strong investment grade rating maintained▶ Adherence to conservative financial policy	

Financial M&A framework



Comfortable liquidity situation through broad mixture of financing sources



Changes in FX rates impact top and bottom lines

Sensitivities* of top 3 foreign currencies - Group, unhedged			Currency management
U.S. \$	Deviation 0.01 U.S. dollar increase versus euro	Impact Group Sales: decrease by ~€15 m Group EBITDA: decrease by ~€7 m	<ul style="list-style-type: none"> Exposure from booked revenues and invoices, receivables and liabilities, are hedged 100% Exposure from planned revenues hedged up to three years on a rolling basis Instruments are forward contracts affecting EBITDA pre of Corporate / Other and options affecting financial result
CH ₣	Deviation 0.01 Swiss franc increase versus euro	Impact Group Sales: negligible Group EBITDA: increase by ~€4 m	
JPN ¥	Deviation 1 Japanese yen increase versus euro	Impact Group Sales: decrease by ~€4 m Group EBITDA: decrease by ~€2 m	

*approximate numbers

Corporate Responsibility has always been an integral part of our corporate culture



We continue to improve our culture of Corporate Responsibility

Targets on responsibility measure for products and people



Product safety

Goal	Establish a global hazard and risk communication system	Status	Implementation of REACH, GHS/CLP and GPS ongoing
------	---	--------	--



Diversity

Goal	Increase % of women in management to at least 25-30%	Status	<ul style="list-style-type: none"> ▪ 2010 = 22% ▪ 2011 = 23% ▪ 2012 = 24%
------	--	--------	--



Supply chain management




Goal	Sustainability in the supply chain	Status	Responsible Sourcing Principles - program ongoing
------	------------------------------------	--------	---



Occupational health and safety

Goal	Reduce work accidents in entire Group; LTIR = 2.5	Status	<p>“BeSafe!” program 2011</p> <ul style="list-style-type: none"> ▪ 2011 LTIR = 2.0 ▪ 2012 LTIR = 2.3
------	---	--------	--

Environmental metrics



Acronyms: REACH = Registration, Evaluation, Authorization and Restriction of Chemicals; GHS/CLP = Globally Harmonized System/Classification, Labeling and Packaging; GPS = Global Product Strategy; LTIR = Long Term Injury Rate

One-time items in Q3 2013

One-time items on EBIT				
[€ m]	Q3 2013		Q3 2012	
	One-time items	thereof D&A	One-time items	thereof D&A
Biopharmaceuticals	36	15	94	11
Consumer Health	1	0	8	0
Performance Materials	-5	0	3	0
Life Science	13	0	7	0
Corporate & Other	4	0	-8	0
Total	49	15	104	11

One-time items in 9M 2013

One-time items on EBIT				
[€ m]	9M 2013		9M 2012	
	One-time items	thereof D&A	One-time items	thereof D&A
Biopharmaceuticals	93	45	326	42
Consumer Health	0	0	14	0
Performance Materials	3	1	-11	0
Life Science	31	0	22	0
Corporate & Other	34	0	177	0
Total	161	46	528	42

Financial Calendar

Date	Event
March 6, 2014	Q4/FY 2013 Earnings Release
May 9, 2014	Annual General Meeting
May 15, 2014	Q1 2014 Earnings Release
August 7, 2014	Q2 2014 Earnings Release
November 13, 2014	Q3 2014 Earnings Release




Investor Relations contact details




Constantin Fest
Head of Investor Relations
+49 6151 72-5271
constantin.fest@emdgroup.com



Alessandra Heinz
Assistant Investor Relations
+49 6151 72-3321
alessandra.heinz@emdgroup.com



Svenja Bundschuh
Assistant Investor Relations
+49 6151 72-3744
svenja.bundschuh@emdgroup.com



Eva Sterzel
AGM, Capital Market Events,
IR-Media
+49 6151 72-5355
eva.sterzel@emdgroup.com



Annett Weber
Institutional Investors / Analysts
+49 6151 72-63723
annett.weber@emdgroup.com



Olliver Lettau
Fixed Income, SRI, Private Investors
+49 6151 72-34409
olliver.lettau@emdgroup.com

Email: investor.relations@emdgroup.com Web: www.emdgroup.com Fax: +49 6151 72-913321